Elimanation of activated but not resting primary human CD4+ and CD8+ T cells by Fas ligand (FasL/Cd95L)-expressing Killer-dendritic cells

Immunobiology

Volumn 208, Issue 5, 2004, Pages 463-475

  Hoves, Sabine ^a   Krause, Stefane W ^a   Herfarth, Hans ^a   Halbritter, Dagmar ^a   Zhang, Huang Ge ^b   Mountz, John D ^b   Schölmerich, Jürgen ^a   Fleck, Martin ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; CD8 ANTIGEN; FAS ANTIGEN; FAS LIGAND; PROTEIN ANTIBODY; FASL PROTEIN, MOUSE; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CELL LINE; CELL MATURATION; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENDRITIC CELL; GENETIC TRANSDUCTION; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOREGULATION; IN VITRO STUDY; KILLER CELL; LYMPHOCYTE PROLIFERATION; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIVISION; CYTOLOGY; IMMUNOLOGY; METABOLISM; MOUSE;

ANIMALS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; DENDRITIC CELLS; FAS LIGAND PROTEIN; HUMANS; MEMBRANE GLYCOPROTEINS; MICE;

EID: 1942454394     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1078/0171-2985-00293     Document Type: Article

References (47)

1. Alam A, Cohen LY, Aouad S and Sekaly RP. 1999. Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells. J. Exp. Med. 190: 1879-1890.
2. Alderson MR, Armitage RJ, Maraskovsky E, Tough TW, Roux E, Schooley K, Ramsdell F and Lynch DH. 1993. Fas transduces activation signals in normal human T lymphocytes. J. Exp. Med 178: 2231-2235.
3. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F and Lynch DH. 1995. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 181: 71-77.
4. Ammon C, Meyer SP, Schwarzfischer L, Krause SW, Andreesen R and Kreutz M. 2000. Comparative analysis of integrin expression on monocyte-derived macrophages and monocyte-derived dendritic cells. Immunology 100: 364-369.
5. Bilbao G, Zhang H, Contreras JL, Zhou T, Feng M, Saito I, Mountz JD and Curiel DT. 1999. Construction of a recombinant adenovirus vector encoding Fas ligand with a CRE/Loxp inducible system. Transplant Proc. 31: 792-793.
6. Collette Y, Benziane A, Razanajaona D and Olive D. 1998. Distinct regulation of T-cell death by CD28 depending on both its aggregation and T-cell receptor triggering: a role for Fas-FasL. Blood 92: 1350-1363.
7. Daniel PT, Kroidl A, Cayeux S, Bargou R, Blankenstein T and Dorken B. 1997. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J. Immunol. 159: 3808-3815.
8. Daniel PT, Scholz C, Westermann J, Dorken B and Pezzutto A. 1998. Dendritic cells prevent CD95 mediated T lymphocyte death through costimulatory signals. Adv. Exp. Med. Biol. 451: 173-177.
9. Dulat HJ, von Grumbkow C, Baars W, Schröder N, Wonigeit K and Schwinzer R. 2001. Down-regulation of human alloinumme responses by genetically engineered expression of CD95 ligand on stimulatory and target cells. Eur. J. Immunol. 31: 2217-2226.
10. Elhalel MD, Huang JH, Schmidt W, Rachmilewitz J and Tykocinski ML. 2003. CTLA-4. FasL induces alloantigen-specific hyporesponsiveness. J. Immunol. 170: 5842-5850.
11. Fleck M, Zhang HG, Kern ER, Hsu HC, Muller-Ladner U and Mountz JD. 2001. Treatment of chronic sialadenitis in a murine model of Sjogren's syndrome by local fasL gene transfer. Arthritis Rheum. 44: 964-973.
12. Gahn B, Siller-Lopez F, Pirooz AD, Yvon E, Gottschalk S, Longnecker R, Brenner MK, Heslop HE, Aguilar-Cordova E and Rooney CM. 2001. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int. J. Cancer 93: 706-713.
13. Georgantas RW, 3rd Leong KW and August JT. 2000. Antigen-specific induction of peripheral T cell tolerance in vivo by codelivery of DNA vectors encoding antigen and Fas ligand. Hum. Gene Ther. 11: 851-858.
14. Graham FL and Prevec L. 1995. Methods for construction of adenovirus vectors. Mol. Biotechnol. 3: 207-220.
15. Hoves S, Krause SW, Halbritter D, Zhang HG, Mountz JD, Scholmerich J and Fleck M. 2003. Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as Killer APC. J. Immunol. 170: 5406-5413.
16. Igney FH and Krammer PH. 2002. Immune escape of tumors: apoptosis resistance and tumor counter-attack. J. Leukoc. Biol. 71: 907-920.
17. Inaba M, Kurasawa K, Mamura M, Kumano K, Saito Y and Iwamoto I. 1999. Primed T cells are more resistant to Fas-mediated activation-induced cell death than naive T cells. J. Immunol. 163: 1315-1320.
18. Jenne L, Schuler G and Steinkasserer A. 2001. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol. 22: 102-107.
19. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J and Enk AH. 1997. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27: 3135-3142.
20. Jonuleit H, Tuting T, Steitz J, Bruck J, Giesecke A, Steinbrink K, Knop J and Enk AH. 2000. Efficient transduction of mature CD83+dendritic cells using recombinant adenovirus suppressed T cell stimulatory capacity. Gene Ther. 7: 249-254.
21. Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, Stanger BZ and Marshak-Rothstein A. 1995. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373: 444-448.
22. Krammer PH. 2000. CD95's deadly mission in the immune system. Nature 407: 789-795.
23. Kusuhara M, Matsue K, Edelbaum D, Loftus J, Takashima A and Matsue H. 2002. Killing of naive T cells by CD95L-transfected dendritic.cells (DC): in vivo study using killer DC-DC hybrids and CD4(+) T cells from DO11.10 mice. Eur. J. Immunol. 32: 1035-1043.
24. Levings MK, Sangregorio R, Sartirana C, Moschin AL, Battaglia M, Orban PC and Roncarolo MG. 2002. Human CD25 + CD4+T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J. Exp. Med. 196: 1335-1346.
25. Lu L, Qian S, Hershberger PA, Rudert WA, Lynch DH and Thomson AW. 1997. Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J. Immunol. 158: 5676-5684.
26. Matsue H, Matsue K, Kusuhara M, Kumamoto T, Okumura K, Yagita H and Takashima A. 2001. Immunosuppressive properties of CD95L-transduced "killer" hybrids created by fusing donor- and recipient-derived dendritic cells. Blood 98: 3465-3472.
27. Matsue H, Matsue K, Walters M, Okumura K, Yagita H and Takashima A. 1999. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells. Nat. Med. 5: 930-937.
28. Min WP, Gorczynski R, Huang XY, Kushida M, Kim P, Obataki M, Lei J, Suri RM and Cattral MS. 2000. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J. Immunol. 164: 161-167.
29. Miyawaki T, Uehara T, Nibu R, Tsuji T, Yachie A, Yonehara S and Taniguchi N. 1992. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J. Immunol. 149: 3753-3758.
30. Refaeli Y, Van Parijs L, London CA, Tschopp J and Abbas AK. 1998. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8: 615-623.
31. Rescigno M, Piguet V, Valzasina B, Lens S, Zubler R, French L, Kindler V, Tschopp J and Ricciardi-Castagnoli P. 2000. Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory responses. J. Exp. Med. 192: 1661-1668.
32. Rouard H, Leon A, Klonjkowski B, Marquet J, Tenneze L, Plonquet A, Agrawal SG, Abastado JP, Eloit M, Farcet JP and Delfau-Larue MH. 2000. Adenoviral transduction. of human 'clinical grade' immature dendritic cells enhances costimulatory molecule expression and T-cell stimulatory capacity. J. Immunol. Methods 241: 69-81.
33. Siegel RM, Chan FK, Chun HJ and Lenardo MJ. 2000. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat. Immunol. 1: 469-474.
34. Strauss G, Knape I, Melzner I and Debatin KM. 2003. Constitutive caspase activation and impaired death-inducing signaling complex formation in CD95-resistant, long-term activated, antigen-specific T cells. J. Immunol. 171: 1172-1182.
35. Suda T, Tanaka M, Miwa K and Nagata S. 1996. Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand. J. Immunol. 157: 3918-3924.
36. Suda T, Hashimoto H, Tanaka M, Ochi T and Nagata S. 1997. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 186: 2045-2050.
37. Van Parijs L and Abbas AK. 1998. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280: 243-248.
38. Varadhachary AS, Perdow SN, Hu C, Ramanarayanan M and Salgame P. 1997. Differential ability of T cell subsets to undergo activation-induced cell death. Proc. Natl. Acad. Sci. USA 94: 5778-5783.
39. Whartenby KA, Straley EE, Kim H, Racke F, Tanavde V, Gorski KS, Cheng L, Pardoll DM and Civin CI. 2002. Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation. Blood 100: 3147-3154.
40. Wolfe T, Asseman C, Hughes A, Matsue H, Takashima A and von Herrath MG. 2002. Reduction of antiviral CD8 lymphocytes in vivo with dendritic cells expressing fas ligand-increased survival of viral (lymphocytic choriomeningitis virus) central nervous system infection. J. Immunol. 169: 4867-4872.
41. Wong B, Arron J and Choi Y. 1997. T cell receptor signals enhance susceptibility to Fas-mediated apoptosis. J. Exp. Med. 186: 1939-1944.
42. Wu B, Wu JM, Miagkov A, Adams RN, Levitsky HI and Drachman DB. 2001. Specific immunotherapy by genetically engineered APCs: the "guided missile" strategy. J. Immunol. 166: 4773-4779.
43. Yolcu ES, Askenasy N, Singh NP, Cherradi SE and Shirwan H. 2002. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 17: 795-808.
44. Zhang HG, Liu D, Heike Y, Yang P, Wang Z, Wang X, Curiel DT, Zhou T and Mountz JD. 1998. Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells. Nat. Biotechnol. 16: 1045-1049.
45. Zhang HG, Su X, Liu D, Liu W, Yang P, Wang Z, Edwards CK, Bluethmann H, Mountz JD and Zhou T. 1999. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells. J. Immunol. 162: 1423-1430.
46. Zhang HG, Fleck M, Kern ER, Liu D, Wang Y, Hsu HC, Yang P, Wang Z, Curiel DT, Zhou T and Mountz JD. 2000. Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient mice. J. Clin. Invest. 105: 813-821.
47. Zhou BB, Li H, Yuan J and Kirschner MW. 1998. Caspase-dependent activation of cyclin-dependent kinases during Fas-induced apoptosis in Jurkat cells. Proc. Natl. Acad. Sci. USA 95: 6785-6790.